NanoString announces Early Access Program for nCounter Elements used in translational research

NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced an Early Access Program for nCounter Elements™, a line of General Purpose Reagents (GPRs) developed specifically to meet the needs of translational research and clinical laboratories. nCounter Elements GPRs enable researchers to independently develop multiplexed genomic assays, and then rapidly translate those assays into clinical diagnostics offered as Laboratory Developed Tests. The company made the announcement at the annual meeting of the American Association for Clinical Chemistry (AACC) taking place in Houston from July 28 - August 1.

Since the completion of the sequencing of the human genome, many clinically relevant biomarkers and signatures have been identified that offer enormous potential to improve human health. However, the rate of translating these discoveries into clinically useful tools has lagged. A major challenge has been developing and validating highly multiplexed assays that can both reliably test clinical samples, such as tissue biopsies stored as Formalin-Fixed Paraffin Embedded (FFPE) samples, and be easily implemented in a clinical laboratory. With nCounter Elements GPRs, this challenge can be met.

"This launch further supports NanoString's vision of helping researchers to advance their understanding of disease, and then directly apply that knowledge to molecular diagnostics," said Brad Gray, President and Chief Executive Officer of NanoString Technologies. "By opening our technology to laboratories developing innovative diagnostics, we can accelerate the growth of our business in clinical laboratories and reach even more patients than we could through the development of in vitro diagnostic products alone."

nCounter Elements is a new digital molecular barcoding chemistry that allows users to assemble their own customized assays using standard sets of barcodes provided by NanoString and probes that they can purchase independently from an oligonucleotide manufacturer. The nCounter Elements reagents have been registered with the Food and Drug Administration as a General Purpose Reagent, and are available for use in developing Laboratory Developed Tests, pursuant to a licensing arrangement to be offered by NanoString. In addition, the highly flexible architecture of nCounter Elements enables a broad range of basic research studies where iterative design and refinement of assays are important.

Laboratories will now be able to independently develop custom, multiplexed assays to detect gene expression, copy number variations, and gene fusions that generate reliable results from a diverse range of sample types including FFPE samples. By enabling rapid, robust analysis of up to 216 targets per reaction with only 3 pipetting steps per sample, nCounter Elements offer translational researchers and clinical laboratories a powerful new tool for developing and validating Laboratory Developed Tests based on recent genomic discoveries.

NanoString has beta-tested the nCounter Elements reagents with existing customers developing potential cancer diagnostics based on gene expression signatures. "We are interested in using nCounter Elements to develop a clinical test based on a gene expression signature that was validated with NanoString's original chemistry," said Cynthia Hawkins, a neuropathologist at the Hospital for Sick Children in Toronto. "A major advantage of nCounter Elements chemistry is its compatibility with FFPE samples. We are pleased that the preliminary results from the nCounter Elements beta testing show high correlation between matched Fresh-Frozen and FFPE samples."

Customers in the Early Access Program will receive the first shipments of nCounter Elements GPRs during the third quarter of 2013. Early access customers will receive a starter package to support initial experiments and have the opportunity to provide feedback on the product prior to full commercialization.

Source:

NanoString Technologies, Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Nanostring. (2019, June 19). NanoString announces Early Access Program for nCounter Elements used in translational research. News-Medical. Retrieved on April 15, 2021 from https://www.news-medical.net/news/20130802/NanoString-announces-Early-Access-Program-for-nCounter-Elements-used-in-translational-research.aspx.

  • MLA

    Nanostring. "NanoString announces Early Access Program for nCounter Elements used in translational research". News-Medical. 15 April 2021. <https://www.news-medical.net/news/20130802/NanoString-announces-Early-Access-Program-for-nCounter-Elements-used-in-translational-research.aspx>.

  • Chicago

    Nanostring. "NanoString announces Early Access Program for nCounter Elements used in translational research". News-Medical. https://www.news-medical.net/news/20130802/NanoString-announces-Early-Access-Program-for-nCounter-Elements-used-in-translational-research.aspx. (accessed April 15, 2021).

  • Harvard

    Nanostring. 2019. NanoString announces Early Access Program for nCounter Elements used in translational research. News-Medical, viewed 15 April 2021, https://www.news-medical.net/news/20130802/NanoString-announces-Early-Access-Program-for-nCounter-Elements-used-in-translational-research.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
NanoString receives license from Health Canada to market Prosigna Breast Cancer Prognostic Gene Signature Assay